Impact of the COVID-19 pandemic on use of anti-dementia medications in 34 European and North American countries.
Alzheimers Dement (N Y)
; 7(1): e12206, 2021.
Article
in English
| MEDLINE | ID: covidwho-1469559
ABSTRACT
INTRODUCTION:
The impact of the COVID-19 pandemic on the global use of anti-dementia medication is unknown. We aimed to determine the changes of anti-dementia medication use in Europe (EU) and North America (NA) during the pandemic.METHODS:
This is a cross-sectional study using sales data of anti-dementia medications in 2019 and 2020 from 34 EU and NA countries. The monthly uses of anti-dementia medications from January through June in 2020 were compared to the corresponding months in 2019 for each country.RESULTS:
In the pre-pandemic period of January to March 2020, 70 out of 102 (3 months x 34 countries) measurements (68.6%) of monthly sales volume showed an increase. In contrast, 76.5% and 85.3% countries showed reduced sales in April and May 2020, respectively.DISCUSSION:
These findings indicate changes in use of anti-dementia medications during the pandemic. The delivery of pharmaceutical care for dementia patients may be heavily disrupted in certain countries.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
/
Observational study
/
Randomized controlled trials
Language:
English
Journal:
Alzheimers Dement (N Y)
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS